News

Meta-Analyses Indicate Asthma Boosts Lung Cancer Risk


 

DENVER — Asthma may be a risk factor for lung cancer, according to two new meta-analyses.

The public health implications of such an association would be enormous. Asthma affects at least 15 million Americans, 40% of them children. Its prevalence has been climbing steadily for decades in developed countries, more than doubling in the United States during a recent 20-year period. And lung cancer is the second most common noncutaneous malignancy in this country, with 10% of lung cancer deaths not attributable to smoking, Chanis Mercado said at the annual meeting of the American Public Health Association.

One of the two meta-analyses she performed as a Ph.D. candidate in public health at the Ponce (P.R.) School of Medicine involved 17 high-quality case-control studies with a total of 54,238 subjects. The conclusion was that individuals with asthma had 34% greater odds of having lung cancer, compared with matched controls without asthma.

A separate meta-analysis that included 16 high-quality cohort studies and 1,384,824 subjects showed that those with asthma were 46% more likely to develop lung cancer than were subjects without asthma.

These results were statistically robust. Eliminating any individual study didn’t substantially change the results. Tests for the existence of publication bias proved reassuringly negative.

One biologically plausible possible mechanism for the observed asthma–lung cancer link is that the persistent chronic inflammation that is a defining feature of asthma causes DNA damage to cells in the airway. Another possibility is that asthma patients have defective clearance of toxins in the bronchioalveolar epithelium, resulting in prolonged local exposure to carcinogens, she said.

The clinical implication of these two meta-analyses is that asthma patients ought to be screened earlier and more often for signs and symptoms of lung cancer, Ms. Mercado continued. This screening might take the form of chest x-rays, sputum cytology tests, and/or a low threshold for acting on symptoms of weight loss or hemoptysis.

Ms. Mercado declared having no relevant financial interests.

Recommended Reading

Scoring System Predicts Recurrent VTE Risk in Cancer Patients
MDedge Internal Medicine
Nilotinib Improves CML Outcomes at 3 Years
MDedge Internal Medicine
FLVCR Function New Target in Fight Against Malaria
MDedge Internal Medicine
Serrated Polyps Together With Adenomas Raise CRC Risk
MDedge Internal Medicine
Sunscreen Found to Cut Melanoma Incidence
MDedge Internal Medicine
Imatinib Plus Bone Marrow Transplant Boost Survival in Ph+ ALL
MDedge Internal Medicine
Survival Improved After Colorectal Liver/Lung Mets Resection
MDedge Internal Medicine
Low-Dose Aspirin Cuts Cancer Death Rate by 30%-40%
MDedge Internal Medicine
Hydroxyurea Cuts Hospitalization, Transfusion in Children with Sickle Cell
MDedge Internal Medicine
Screening Mammography Rates Are Below Guideline Recommendations
MDedge Internal Medicine